Research Analysts Set Expectations for TCRX FY2029 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Analysts at HC Wainwright issued their FY2029 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Thursday, March 6th. HC Wainwright analyst A. Fein expects that the company will earn $0.44 per share for the year. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Wednesday, March 5th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). The business had revenue of $0.67 million for the quarter, compared to the consensus estimate of $1.43 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.

Several other research analysts have also recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research note on Wednesday. Needham & Company LLC dropped their price objective on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Barclays dropped their price objective on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a research note on Friday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, TScan Therapeutics presently has a consensus rating of “Buy” and an average price target of $9.20.

TScan Therapeutics Trading Down 4.8 %

TCRX opened at $1.98 on Friday. The stock has a market cap of $105.67 million, a price-to-earnings ratio of -1.87 and a beta of 0.91. The stock’s 50 day moving average price is $2.41 and its 200-day moving average price is $4.00. TScan Therapeutics has a one year low of $1.82 and a one year high of $9.69. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

Institutional Trading of TScan Therapeutics

A number of hedge funds have recently bought and sold shares of TCRX. Brown Brothers Harriman & Co. lifted its holdings in TScan Therapeutics by 88.2% during the third quarter. Brown Brothers Harriman & Co. now owns 143,051 shares of the company’s stock worth $712,000 after buying an additional 67,027 shares during the period. Great Point Partners LLC lifted its holdings in TScan Therapeutics by 8.0% during the third quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock worth $5,062,000 after buying an additional 75,544 shares during the period. MetLife Investment Management LLC lifted its holdings in TScan Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after buying an additional 13,164 shares during the period. Checkpoint Capital L.P. purchased a new stake in TScan Therapeutics during the third quarter worth $4,110,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in TScan Therapeutics during the third quarter worth $515,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.